Apple Removes All References to Controversial CSAM Scanning Feature From Its Child Safety Webpage

Apple has quietly nixed all mentions of CSAM from its Child Safety webpage, suggesting its controversial plan to detect child sexual abuse images on iPhones and iPads may hang in the balance following significant criticism of its methods.

Apple in August announced a planned suite of new child safety features, including scanning users’ iCloud Photos libraries for Child Sexual Abuse Material (CSAM), Communication Safety to warn children and their parents when receiving or sending sexually explicit photos, and expanded CSAM guidance in Siri and Search.

Following their announcement, the features were criticized by a wide range of individuals and organizations, including security researchers, the privacy whistleblower Edward Snowden, the Electronic Frontier Foundation (EFF), Facebook’s former security chief, politicians, policy groups, university researchers, and even some Apple employees.


まもなくやってくる2021年のホリデーシーズンは、サプライチェーンのボトルネックや配送サービスの需要の高まりで物流が混乱すると予想されている。配送大手United Parcel Service of America(UPS)とWaymoもこのことを認識している。Waymoは米国時間11月17日、この期間にUPSを支援すると発表した。自動運転トラックによる輸送サービス「Waymo Via」が、UPSの配送業務を試験的に支援する。

Waymoは今回の提携拡大について、これまでに成功してきたUPSとの強力なパートナーシップに続く「ごく自然な次の段階」だとしている。この新たな取り組みでは、米国でクラス8に分類される大型トラックに第5世代の「Waymo Driver」自動運転システムを搭載し、試験的に配送を行う。




走行距離は片道約3.2キロメートルで、全長は6.4キロメートル。速度時速20キロメートル未満で停留所が全6カ所、所要時間が片道約20分の全区画を自動運転する。住民の日常的な移動手段や「かみしほろシェア OFFICE」「かみしほろワーケーションパック」などのワーケーション用途、観光などを目的とする来訪者の2次交通としての活用を想定しているという。






Giant Study Finds Viagra Is Linked to Almost 70% Lower Risk of Alzheimer’s

Usage of the medication sildenafil – better known to most as the brand-name drug Viagra – is associated with dramatically reduced incidence of Alzheimer’s disease, new research suggests.

According to a study led by researchers at the Cleveland Clinic, taking sildenafil is tied to a nearly 70 percent lower risk of developing Alzheimer’s compared to non-users.

That’s based on an analysis of health insurance claim data from over 7.2 million people, in which records showed that claimants who took the medication were much less likely to develop Alzheimer’s over the next six years of follow up, compared to matched control patients who didn’t use sildenafil.

It’s important to note that observed associations like this – even on a huge scale – are not the same as proof of a causative effect. For example, it’s possible that the people in the cohort who took sildenafil might have something else to thank for their improved chances of not developing Alzheimer’s.